Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.
Crop Life Science's current deferred revenue for the quarter that ended in Mar. 2026 was ₹0 Mil.
Crop Life Science Current Deferred Revenue Related Terms
Crop Life Science Current Deferred Revenue Historical Data
* Premium members only.
The historical data trend for Crop Life Science's Current Deferred Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Current Deferred Revenue of ₹0 Mil mean?
Crop Life Science (NSE:CLSL) has a Current Deferred Revenue of ₹0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Crop Life Science and its competitors.
Is Crop Life Science's Current Deferred Revenue too high?
Crop Life Science's current Current Deferred Revenue is ₹0 Mil. Overall, Crop Life Science has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crop Life Science's Current Deferred Revenue compare to CTVA and CF?
Crop Life Science's Current Deferred Revenue of ₹0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for an Agriculture company?
A good Current Deferred Revenue depends on the Agriculture industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Crop Life Science and its competitors. Crop Life Science's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crop Life Science stock overvalued right now?
Based on GuruFocus' analysis, Crop Life Science (NSE:CLSL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹55.65, compared to a current price of ₹62.00 — trading 11.4% above its estimated fair value. The current Current Deferred Revenue is ₹0 Mil. Crop Life Science's overall GF Score™ is 55/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Crop Life Science (NSE:CLSL), the current Current Deferred Revenue is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crop Life Science (NSE:CLSL) Overvalued in 2026?
Based on GuruFocus' analysis, Crop Life Science stock appears to be overvalued.
The current stock price of ₹62.00 is trading 11.4% above its estimated GF Value™ of ₹55.65.
GuruFocus considers Crop Life Science to be Modestly Overvalued.
Key valuation signals for NSE:CLSL:
Current Deferred Revenue: ₹0 Mil
GF Value™: ₹55.65 vs. price of ₹62.00 (11.4% above fair value)
No single metric tells the full story. See the NSE:CLSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crop Life Science Ltd manufactures and distributes a broad range of crop protection chemicals, including pesticides, insecticides, fungicides, herbicides, micro fertilizers, bio-pesticides, bio-fertilizers, plant growth regulators, and soil plant health products. The company operates its manufacturing facility in Ankleshwar, Gujarat, leveraging technology to maintain quality standards. It serves agricultural markets within India and exports to countries including Indonesia, Bangladesh, Egypt, Myanmar, Vietnam, and Sudan. Segments include Agro chemicals and Agro trade. Revenue is generated through the sale of its agricultural chemicals and related products to farmers, distributors, and agri-businesses.
55GF Score
Get the complete analysis for NSE:CLSL
Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CLSL has been successfully added to your 
